TREATMENT REGIMENS

Day 1:
Vinorelbine 30mg/m²

DOSING

Day 1:
Vinorelbine 25–30mg/m²

Days 1, 8, and 15:

First-line Combination¹

Note: All recommendations are Category 2A unless otherwise indicated.

RECOMMENDATIONS

Pemetrexed + cisplatin (Category 1)²

Day 1: Pemetrexed 500mg/m² IV day 1 followed 30 minutes later by cisplatin 75mg/m² over 2 hours. Repeat every 21 days up to 12 cycles.

Pemetrexed + cisplatin + bevacizumab (Category 1)³,⁴

Day 1: Pemetrexed 500mg/m² IV + cisplatin 75mg/m² IV + bevacizumab 15mg/kg IV. Repeat every 21 days for 6 cycles, followed by: Maintenance bevacizumab 15mg/kg every 21 days until disease progression.

Pemetrexed + carboplatin⁵,⁶

Day 1: Pemetrexed 500mg/m² IV and carboplatin AUC 5mg·min/mL IV. Repeat every 21 days for a max of 9 cycles.

Gemcitabine + cisplatin⁶,⁷

Day 1: Cisplatin 80–100mg/m² IV over 1 hour Days 1, 8, and 15: Gemcitabine 1000–1250mg/m² IV over 30 minutes. Repeat every 21-28 days for 6 cycles.

Pemetrexed⁸

Day 1: Pemetrexed 500mg/m² IV. Repeat every 21 days for 4 cycles.

Vinorelbine⁹

Vinorelbine 25–30mg/m² (max 60mg) IV every week for 12 weeks.

Subsequent Systemic Therapy¹⁰

Pemetrexed (if not administered as first-line) (Category 1)¹¹,¹²

Day 1: Pemetrexed 500mg/m² IV. Repeat every 3 weeks for 8 cycles.

Vinorelbine¹³,¹⁴

Vinorelbine 30mg/m² (max 60mg) IV weekly. Repeat every 6 weeks for 11 cycles.

Gemcitabine¹⁴,¹⁶

Days 1, 8, and 15: Gemcitabine 1250mg/m² IV. Repeat every 28 days for a max of 10 cycles.

Nivolumab ± ipilimumab¹⁷

Day 1: Nivolumab 3mg/kg IV over 1 hour every 2 weeks Day 1: Ipilimumab 1mg/kg IV over 1.5 hours every 6 weeks. Repeat until disease progression or unacceptable toxicity.

Pembrolizumab¹⁸

Day 1: Pembrolizumab 10mg/kg IV every 2 weeks. Repeat for 2 years or until disease progression or unacceptable toxicity.

Notes:
- The combination regimen of pemetrexed + cisplatin + bevacizumab is only for unresectable disease.
- Consider rechallenge if good sustained response at the time initial chemotherapy was interrupted.
- The carboplatin/pemetrexed regimen is recommended for patients with poor performance score and/or comorbidities.

References
References (continued)


*Revised 12/2017*  
© 2017 Haymarket Media, Inc.